Indexes of innate and adaptive immunity in the patients with SARS-CoV-2 infection

Cover Page


Cite item

Full Text

Abstract

The main pathogenetic mechanisms of the SARS-CoV-2 infection include imbalance of immune response and impaired cytokine regulation involving insufficient interferon synthesis at the onset of the disease, and subsequent hyperproduction of proinflammatory cytokines resulting in marked inflammation and damage of pulmonary parenchyma. Our objective was to perform monitoring of cytokine content, determination of antibodies, immune cells, and inflammatory biomarkers in the patients who had coronavirus infection caused by COVID-19, during the disease and over the convalescence period. The study included sixty patients at the age of 18 y.o. and older with severe and moderate course of disease caused by COVID-19. The diagnosis was verified in accordance with provisional instructional guidelines of the Ministry of Healthcare of the Russian Federation “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)” version 11 (17.05.2021). The study involved analysis of medical documents, evaluation of differential white blood cell count, T cell subpopulations, C-reactive ptrotein (CRP) levels, interleukin-6 (IL-6), interferon gamma (IFNγ), tumor necrosis factor-alpha (TNFα), as well as IgM and IgG antibodies against SARS-CoV-2.
Statistical processing of data was performed by Statistica 13 program with critical significance level p < 0.05, correlations were analyzed using Spearman rank correlation coefficient, multidimensional correlation analysis with creation of pleiads, according to V.P. Terentyev’s method (1959), and Shapiro–Wilk testing for normality of data distributions. The sample size made it possible to evaluate the results at a significance of 95-99%. These studies have yielded the results concerning specific changes of the inflammatory biomarkers at different stages of disease, persistent changes in quantitative and qualitative characteristics of immune cells and cytokine levels, correlations between immunological indicators and severity of clinical course, and degree of damage to pulmonary parenchyma. During the period of significant clinical presentations, the patients with severe course of disease exhibited leukopenia with low proportion of lymphocytes, and maintenance of CRP and ESR at high levels for longer terms, including early recovery. Levels and changes in amounts of IgG and IgM antibodies to SАRS-CoV-2 varied in accordance with clinical severity and duration of convalescence period. During the recovery period, an imbalance of regulatory T cell subpopulations and low levels of IFNγ were observed. The stable impairment of structural and functional characteristics of immune cells and aberrant production of cytokines during the disease caused by SARS-CoV-2 may serve as a pre-requisite for monitoring immunological indices in search for personalized immunotropic therapy.

About the authors

T. S. Sitdikova

Pacific State Medical University;
City Polyclinic No. 3 

Author for correspondence.
Email: sestrichka_1985@mail.ru
ORCID iD: 0000-0001-5682-1105

PhD (Medicine), Allergologist and Clinical Immunologist, Assistant Professor, Department of Clinical Laboratory Diagnostics, General and Clinical Immunology; Head

 690014, Russian Federation, Vladivostok, Krasnogo Znameni ave., 117d, apt 191

Phone: 7 (924) 234-09-18 

Russian Federation

A. A. Kabieva

City Polyclinic No. 3

Email: angella.vl@mail.ru

 Chief Physician; Chief Regional Specialist for Medical Prevention 

 Vladivostok 

Russian Federation

E. V. Prosekova

Pacific State Medical University

Email: pros.ev@mail.ru
ORCID iD: 0000-0001-6632-9800

PhD, MD (Medicine), Professor, Head, Department of Clinical Laboratory Diagnostics and General and Clinical Immunology 

 Vladivostok 

Russian Federation

References

  1. Абдуллаев Р.Ю., Комиссарова О.Г. Изменения маркеров гематологического, биохимического и коагулологического анализов крови при новой коронавирусной инфекции COVID-19//Consilium medicum. – 2020. – Т. 22, № 11. - С. 51-5
  2. Амвросьева Т.В.,Поклонская Н.В. SARS-CoV 2: лабораторная диагностика// Наука и инновации. - 2020. - № 7. - С. 22–27
  3. Баклаушев В.П.,Кулемзин С.В.,Горчаков А.А. COVID-19. Этиология, патогенез, диагностика и лечение// Клиническая практика. – 2020. – Т. 11. – № 1. – С. 7–2
  4. Бугоркова С.А. Некоторые аспекты формирования иммунного ответа у пациентов с COVID-19. COVID-19 Preprints [Preprint]. 2020. URL: https://covid19-preprints.microbe.ru/ article/21.
  5. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11 (07.05.2021) – 224 с.
  6. Елеукина А.А., Коржумбаев А.Н., Акшалов А.Р.Изменение С-реактивного белка в сыворотке крови при коронавирусной и бактериальной пневмонии//Тенденции развития науки и образования.-2021.-№74-1.-С. 43-48
  7. Климов Н.А., Симбирцев А.С. СOVID-19: особенности патогенеза заболевания и мишени для иммунотерапевтического воздействия//Медицинский академический журнал. -2020.-Т.20.-№3.-С. 75-88
  8. Пащенков М.В., Хаитов М.Р. Иммунный ответ против эпидемических коронавирусов// Иммунология. –2020. – Т. 41. – № 1. – С. 5–18
  9. Хайдуков С.В., Байдун Л.А., Зурочка А.В., Тотолян А.А. Стандартизованная технология "исследование субпопуляционного состава лимфоцитов периферической крови с применением проточных цитофлюориметров-анализаторов»//Российский иммунологический журнал. -2014.-Т.8.-№4.-С.974-92
  10. Garcia L.F. Immuneresponse, inflammation,andtheclinical spectrum of СОVID-19. Front Immunol., 2020, no.11, pp.1441.
  11. Guan W.J., Ni Z.Y., Hu Y. China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, 382;18, pp. 1708-1720
  12. Hou H.,Wang T., Zhang B., Luo Y., Mao L., Wang F. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl. Immunology., 2020 , Vol. 9, no 5, pp. e01136(5): e01136.
  13. Leisman D.E., Ronner L., Pinotti R. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, metaanalysis, and comparison with other inflammatory syndromes. The Lancet Respiratory Medicine., 2020, Vol. 8., Is.12., pp. 1233-1244
  14. Liu Y. C., Yang Y., Zhang C. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci., 2020, Vol.63(3), pp. 364–74
  15. Remy K.E., Mazer M., Striker D.A.Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight., 2020, Vol. 5., Is. 17., pp. 1-15.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Sitdikova T.S., Kabieva A.A., Prosekova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies